Peptide-Drug Conjugates: The Next Evolution Beyond Antibody-Drug Conjugates for Cancer Treatment | Research

The takeaway

Peptide-drug conjugates (PDCs) offer advantages over antibody-drug conjugates including easier manufacturing, better tissue penetration, and lower immune toxicity, but face challenges in pharmacokinetics and bioactivity that need solving.

Multiple PDCs in clinical trials
Peptide-drug conjugates offer easier manufacturing, higher tissue penetration, and lower immunotoxicity than antibody-drug conjugates, with several candidates now advancing through human testing

What the researchers found

PDCs offer several advantages over ADCs: more accessible industrial synthesis, versatile functionalization, high tissue penetration, rapid clearance, and low immunotoxicity. Three peptide categories serve different delivery functions — tumor-targeting peptides for specificity, cell-penetrating peptides for intracellular delivery, and self-assembling peptides for controlled release and nanostructure formation. PDCs can overcome drug resistance, control drug release, and improve efficacy while reducing off-target toxicity. However, poor pharmacokinetic properties and low bioactivity remain the primary clinical development challenges.

Why it matters

ADCs represent a multi-billion-dollar cancer drug market, but their large antibody size limits tissue penetration and manufacturing is complex and expensive. If PDCs can overcome their current pharmacokinetic limitations, they could democratize targeted cancer therapy — being cheaper to produce, easier to modify, and capable of reaching tumors that antibodies cannot. With several PDCs now in clinical trials, this technology is approaching real-world clinical impact.

How the study worked

Comprehensive narrative review analyzing PDC design principles (informed by ADC success factors), component functions (peptides, linkers, payloads), peptide categories, pharmacokinetics, and current clinical trial landscape. The review draws comparisons between PDCs and established ADC technology throughout.

What this study cannot tell us

As a narrative review, this does not include systematic methodology or meta-analysis. The comparison between PDCs and ADCs is partially theoretical — very few PDCs have completed late-stage clinical trials, so the real-world performance gap remains uncertain. The challenges highlighted (pharmacokinetics, bioactivity) are significant and may limit which tumor types PDCs can effectively treat. Self-assembling peptide systems are particularly early in development.

How to read the evidence

This is a comprehensive narrative review of an emerging drug class. While it provides an excellent overview of the technology, design principles, and clinical pipeline, the PDC field itself has limited clinical evidence compared to the well-established ADC class.

When this study was published

Published in 2025, this review captures the PDC field at a pivotal moment as candidates advance through clinical trials. It provides the most current overview of the technology's state and challenges.

The bigger picture

The PDC field sits at the intersection of two major pharmaceutical trends: the explosion of targeted cancer therapies (led by ADCs) and the maturation of peptide therapeutics. ADCs like trastuzumab deruxtecan have shown transformative clinical results, but their manufacturing complexity and cost limit global access. PDCs could potentially deliver similar targeted therapy at a fraction of the cost, with the added ability to reach solid tumors that large antibodies struggle to penetrate. This review provides a roadmap for the field at a critical inflection point.

Questions still open

Can PDC pharmacokinetic challenges be solved through peptide engineering without sacrificing their manufacturing simplicity?
Which cancer types are most amenable to PDC therapy given their rapid clearance profile?
Will PDCs ultimately complement ADCs for specific clinical niches or compete directly with them?

Common questions

What is a peptide-drug conjugate and how is it different from an antibody-drug conjugate?

Both are targeted cancer treatments that deliver toxic drugs directly to tumor cells. ADCs use large antibody proteins (~150 kDa) as the delivery vehicle, while PDCs use much smaller peptides (~1-5 kDa). This size difference gives PDCs better tissue penetration, easier manufacturing, and lower immune reactions — but also faster clearance from the body, which can reduce their effectiveness.

Are peptide-drug conjugates available as cancer treatments?

Not yet as approved drugs, but several are in clinical trials. While ADCs like Enhertu and Adcetris are already widely used, PDCs are still proving their clinical worth. The technology is advancing rapidly, and the advantages PDCs offer — especially in manufacturing cost and tissue penetration — could make them particularly important for expanding global access to targeted cancer therapy.

Read the original research

Current progress and remaining challenges of peptide-drug conjugates (PDCs): next generation of antibody-drug conjugates (ADCs)?

Journal of nanobiotechnology, 23(1), 305

View on PubMed ↗Publisher’s paper ↗

Citation

Wang, Dongyuan; Yin, Feng; Li, Zigang; Zhang, Yu; Shi, Chen. (2025). Current progress and remaining challenges of peptide-drug conjugates (PDCs): next generation of antibody-drug conjugates (ADCs)?. Journal of nanobiotechnology, 23(1), 305. https://doi.org/10.1186/s12951-025-03277-2